Top in allergy/asthma: Risk factors for chronic rhinosinusitis; update on omalizumab
Click Here to Manage Email Alerts
Researchers traced childhood illnesses like asthma, frequent head colds and tonsilitis to the development of chronic rhinosinusitis in middle age in a population-based study.
Treating some of those childhood illnesses could potentially prevent chronic rhinosinusitis (CRS) from developing later in life, they suggested.
“For doctors managing children for frequent head colds and/or recurrent tonsillitis, prescribing antibiotics earlier and more often might lessen a child’s future risk for CRS from bacterial infections of the upper airway,” Jennifer Perret, MBBS, FRACP, PhD, physician-trained respiratory and sleep epidemiologist .
“For doctors who have diagnosed and are treating middle-aged patients with CRS symptoms, they can also actively seek a history and look for signs of asthma and allergies which could be treated as well”
It was the top story in allergy/asthma last week.
In another top story, Tina L.R. Dominguez, PA-C, MMS, a food allergy specialist and the East Bay clinical director at Latitude Food Allergy Care clinic in San Ramon, California, provide insight on how omalizumab (Xolair) has affected patients and insurance coverage since receiving FDA approval.
Read these and more top stories in allergy/asthma below:
Childhood illnesses associated with risks for chronic rhinosinusitis in middle age
Children with asthma, frequent head colds and tonsilitis at age 7 years face greater risks for chronic rhinosinusitis in middle age and may benefit from closer monitoring and proactive management, according to a study published in Allergy. Read more.
Omalizumab rollout for food allergy patients requires care
In February, the FDA approved omalizumab for the reduction of food allergic reactions. First approved in 2003 for allergic asthma, this anti-IgE monoclonal antibody developed by Genentech and Novartis inhibits the allergic reaction process. The second part of the study that encouraged FDA approval will be published in August Read more.
Baricitinib, dupilumab see comparable real-world results in atopic dermatitis
Responses to baricitinib (Olumiant, Eli Lilly) and dupilumab (Dupixent Regeneron, Sanofi) were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Caregivers respond well after administering epinephrine during child oral food challenge
Giving young children an epinephrine autoinjection can be a positive and confidence-boosting experience for families, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Rhinovirus infections associated with severe recurrent wheeze among children
Asymptomatic rhinovirus lung infections may accompany severe recurrent wheeze in children, with granulocytic bronchoalveolitis and elevated inflammation, according to a study published in The Journal of Allergy and Clinical Immunology. Read more.